REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from HC Wainwright

REGENXBIO (NASDAQ:RGNXGet Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $36.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 410.64% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Raymond James reissued an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price objective on shares of REGENXBIO in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, REGENXBIO presently has an average rating of “Moderate Buy” and an average price target of $35.27.

Get Our Latest Report on REGENXBIO

REGENXBIO Stock Performance

REGENXBIO stock opened at $7.05 on Wednesday. The stock has a 50-day simple moving average of $8.91 and a 200-day simple moving average of $10.56. The company has a market capitalization of $349.29 million, a P/E ratio of -1.40 and a beta of 1.28. REGENXBIO has a fifty-two week low of $6.56 and a fifty-two week high of $28.80.

Institutional Investors Weigh In On REGENXBIO

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares during the last quarter. FMR LLC boosted its holdings in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the last quarter. nVerses Capital LLC increased its stake in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after buying an additional 3,720 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in REGENXBIO by 20.6% in the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,997 shares during the period. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Featured Stories

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.